Basal ganglia volumes in drug-naive first-episode schizophrenia patients before and after short-term treatment with either a typical or an atypical antipsychotic drug

2007 ◽  
Vol 154 (3) ◽  
pp. 199-208 ◽  
Author(s):  
Andreas Glenthoj ◽  
Birte Y. Glenthoj ◽  
Torben Mackeprang ◽  
Anne K. Pagsberg ◽  
Ralf P. Hemmingsen ◽  
...  
Keyword(s):  
Basal Ganglia ◽  
Atypical Antipsychotic ◽  
Term Treatment ◽  
First Episode ◽  
Short Term ◽  
Short Term Treatment ◽  
Atypical Antipsychotic Drug ◽  
Before And After ◽  
Drug Naïve ◽  
First Episode Schizophrenia

scholarly journals Changes in three tumor markers in patients with advanced lung adenocarcinoma after combination therapy with pemetrexed and platinum: Short-term treatment efficacy

2021 ◽  
Vol 18 (3) ◽  
pp. 619-623
Author(s):  
Yang Lou ◽  
Bo Xu ◽  
Xianshuai Li ◽  
Xiaoyi Xu ◽  
Xianguo Chen
Keyword(s):  
Lung Adenocarcinoma ◽  
Tumor Markers ◽  
Tumor Volume ◽  
Term Treatment ◽  
Term Therapy ◽  
Research Subjects ◽  
Short Term ◽  
Short Term Treatment ◽  
Before And After ◽  
Volume Group

Purpose: To study changes in three tumor markers before and after combination treatment with pemetrexed and platinum, and evaluate the short-term therapeutic effectiveness of the treatment in advanced lung adenocarcinoma (ALA) subjects. Method: Patients with ALA (n =120) admitted to JinHua Municipal Central Hospital from January 2017 to May 2018 were selected as the research subjects. According to the results of chemotherapy, they were divided into two groups: significantly-reduced tumor volume group (90 cases), and nonsignificantly-reduced tumor volume group (21 cases). The two groups were treated with chemotherapy using a combination of pemetrexed and cisplatin. The levels of CEA, CA125 and CYFRA21-1 before and after chemotherapy were assayed to determine their relationship with short-term therapy effectiveness. Result: Overall analysis of tumor markers in the 120 patients with ALA showed statistically significant reduction in overall tumor marker levels before and after chemotherapy (p < 0.05). At the end of chemotherapy, the tumor markers were markedly reduced in subjects with significant tumor volume, and there was statistical difference between the two groups before chemotherapy (p < 0.05). Changes in CEA, CA125 and CYFRA21-1 were positively correlated with the chemotherapeutic effects on patients with ALA. Conclusion: In ALA patients treated with pemetrexed and platinum, changes in serum CEA, CA125 and CYFRA21-1 profiles before and after treatment depend on the effect of chemotherapy, and they are reliable for prediction of short-term therapeutic efficacy.

Sign in / Sign up

Export Citation Format

Share Document